Evidence map›Paper›PMID 36680200›Full record

ArticleViruses2023

Anti-Entry Activity of Natural Flavonoids against SARS-CoV-2 by Targeting Spike RBD.

Jie-Ru Meng, Jiazheng Liu, Lu Fu, Tong Shu, Lingzhi Yang, Xueji Zhang, Zhi-Hong Jiang, Li-Ping Bai

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Chemical Compositions ofInternational journal of molecular sciences · 2024
    Article
  9. Review
  10. Natural products as a source of Coronavirus entry inhibitors.Frontiers in cellular and infection microbiology · 2024
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jie-Ru MengState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa 999078, China.
Jiazheng LiuState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa 999078, China.
Lu FuState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa 999078, China.
Tong ShuSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518060, China.ORCID 0000-0003-1438-8600
Lingzhi YangSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Xueji ZhangSchool of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Zhi-Hong JiangState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa 999078, China.ORCID 0000-0002-7956-2481
Li-Ping BaiState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa 999078, China.ORCID 0000-0002-2806-6883
Macau University of Science and Technology · MOShenzhen University Health Science Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is still a global public health concern, and the SARS-CoV-2 mutations require more effective antiviral agents. In this study, the antiviral entry activity of thirty-one flavonoids was systematically evaluated by a SARS-CoV-2 pseudovirus model. Twenty-four flavonoids exhibited antiviral entry activity with IC

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsFlavonoidsFlavonolsHumansMolecular Docking SimulationProtein BindingSpike Glycoprotein, CoronavirusAntiviral AgentsFlavonoidsFlavonolsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antiviral activityflavonoidSARS-CoV-2structure–activity relationshipviral entry inhibitor

Identifiers

PMID36680200
PMCPMC9862759
OpenAlexW4313578034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.